Chembio Diagnostics, Inc.
CEMI · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $9 | $11 | $9 | $19 |
| % Growth | -18.2% | 22.3% | -51.3% | – |
| Cost of Goods Sold | $6 | $10 | $8 | $15 |
| Gross Profit | $4 | $2 | $1 | $4 |
| % Margin | 38.8% | 13.8% | 11.7% | 19.1% |
| R&D Expenses | $2 | $2 | $2 | $2 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $7 | $6 | $5 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | $0 | $0 |
| Operating Expenses | $7 | $7 | $7 | $9 |
| Operating Income | -$3 | -$6 | -$6 | -$8 |
| % Margin | -36.9% | -53.5% | -67.9% | -42.8% |
| Other Income/Exp. Net | $3 | -$1 | -$1 | -$1 |
| Pre-Tax Income | -$1 | -$7 | -$7 | -$9 |
| Tax Expense | $0 | $2 | $0 | $0 |
| Net Income | -$1 | -$7 | -$7 | -$9 |
| % Margin | -9.3% | -59.8% | -75.8% | -46.7% |
| EPS | -0.035 | -0.26 | -0.23 | -0.29 |
| % Growth | 86.5% | -13% | 20.7% | – |
| EPS Diluted | -0.035 | -0.26 | -0.23 | -0.29 |
| Weighted Avg Shares Out | 24 | 32 | 30 | 30 |
| Weighted Avg Shares Out Dil | 24 | 32 | 30 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | $2 | -$5 | -$6 | -$10 |
| % Margin | 16.5% | -45.7% | -61.2% | -51.9% |